Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Covance Not Hurrying to Build More China Facilities

publication date: Oct 31, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Following the collapse of its Joint Venture arrangement with WuXi PharmaTech, Covance will build its own China CRO facilities, but the company does not feel any great pressure to get the job done quickly. The reason? China’s current cost advantage will soon disappear, as wages for scientists in China approach those in the west, according to Joe Herring, CEO of Covance. Covance does $1.5 billion worth of CRO business around the world. Apparently, it does not feel as though it is losing a great deal of contracts to its China-based competitors. More details...

Stock Symbols: (NYSE: CVD) (NYSE: WX)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...